文献速递细菌感染、耐药与抗菌药物

直接口服阿莫西林激发试验用于低风险青霉素过敏标签患者是否可行

Is direct oral amoxicillin challenge a viable approach for 'low-risk' patients labelled with penicillin allergy?
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本文关注被标记为青霉素过敏(PenA)但实际过敏比例很低的现象:人群中高达10%、住院患者中20%被标记为PenA,而经全面检查仅<5%-10%证实过敏。文章认为,在依据指南进行风险分层后筛选出的低风险患者中,不经皮试而直接进行监督下口服阿莫西林激发试验是安全选项,但尚需在常规临床实践中进一步验证。

要点

  • 被标记为青霉素过敏者中经全面检查证实过敏的比例<5%-10%,多数标签不实。
  • 青霉素过敏检测需专业人员且资源有限,导致患者改用替代抗生素。
  • 替代抗生素与医源性感染、耐药及住院时间延长和费用增加相关。

核心结论

  • 在依据指南仔细风险分层选出的低风险患者中,监督下直接口服阿莫西林激发试验是安全选项。
  • 该做法仍需在常规临床实践中验证,并需探索不同医疗环境下的促进与阻碍因素。

研究设计与样本

  • 本文为综述性文章,汇总近期证据讨论直接口服阿莫西林激发试验用于低风险青霉素过敏标签患者的可行性。

主要发现

  • 高达10%的人群和20%的住院患者被标记为青霉素过敏。
  • 经全面检查后仅<5%-10%被证实过敏。
  • 青霉素过敏检测耗费人力并需专科支持,过敏服务有限时难以获得。
  • 被标记PenA的患者接受替代抗生素,与更高的医源性感染率、抗菌药物耐药、住院时间延长及费用增加相关。

关键数值与推荐

  • 患者选择基于仔细的、指南为基础的风险分层流程,低风险指依据病史最不可能过敏者。
  • 直接口服阿莫西林激发试验为监督下进行、不先行过敏检测。

临床怎么用

  • 对病史提示低风险的青霉素过敏标签患者,可按指南风险分层后考虑监督下直接口服阿莫西林激发试验,以减少不必要的替代抗生素使用。

局限性

  • 该干预尚需在常规临床实践中进一步验证。
  • 在不同医疗环境下实施的促进与阻碍因素尚待探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Spurious penicillin allergy (PenA) is a major public health problem. Up to 10% of the population and 20% of inpatients are labelled with PenA, but only <5%-10% have a proven allergy following comprehensive investigations. PenA tests are labour intensive and require specialist input, which may not be readily available due to limited allergy services. Therefore, patients with PenA receive alternative antibiotics that are associated with higher rates of iatrogenic infections, antimicrobial resistance and a longer hospital stay with consequent increased costs. Recent evidence suggests that a supervised 'direct' oral amoxicillin challenge (without performing allergy tests) is a safe option in low-risk patients (those least likely to be allergic based on history). Patient selection for this procedure is based on a careful guideline-based risk stratification process. Further research is needed to validate this intervention in routine clinical practice and explore potential facilitators and barriers to implementation in different healthcare settings.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Krishna MT, Misbah SA. Is direct oral amoxicillin challenge a viable approach for 'low-risk' patients labelled with penicillin allergy? J Antimicrob Chemother. 2019. PMID: 31167024. doi:10.1093/jac/dkz229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。